Pertuzumab + Trastuzumab (PH) Versus PH Plus Metronomic Chemotherapy (PHM) in the Elderly HER2+ Metastatic Breast Cancer Population Who May Continue on T-DM1 Alone Following Disease Progression While on PH / PHM: an Open-label Multicentre Randomized Phase II Selection Trial of the EORTC Elderly Task Force and Breast Cancer Group
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Trastuzumab emtansine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 25 Oct 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2016.
- 14 Jul 2016 Planned End Date changed from 1 Jul 2018 to 1 Sep 2018.
- 14 Jul 2016 Status changed from recruiting to active, no longer recruiting.